Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1380017 | 1.00 | GCK (0.75) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1380710 | 0.92 | GCK (0.65) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1377774 | 0.91 | GCK (0.77) | GCKKCNH2 | |
| SCHEMBL1654969 | 0.86 | GCK (0.78) | GCKKCNH2 | |
| SCHEMBL1426965 | 0.86 | GCK (0.78) | GCKKCNH2 | |
| SCHEMBL1384872 | 0.86 | GCK (0.78) | GCKKCNH2 | |
| SCHEMBL1426806 | 0.86 | GCK (0.83) | GCKKCNH2 | |
| SCHEMBL1427266 | 0.86 | GCK (1.00) | GCKKCNH2 | |
| SCHEMBL1655054 | 0.85 | GCK (0.80) | GCKKCNH2 | |
| SCHEMBL1426413 | 0.85 | GCK (0.80) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301929-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (Publ) (SE) | 2011-03-30 | — | — | EP | disclosed |